Artículos seleccionados

El experto opina

Artículos seleccionados

  Artículos seleccionados |  Jueves, 20 Junio 2019 08:04

Hofer MP, Hedman H, Mavris M, Koenig F, Vetter T, Posch M, et al. Marketing authorisation of orphan medicines in Europe from 2000 to 2013. Drug Discov Today. 2018; 23(2): 424-433.

  Artículos seleccionados |  Lunes, 20 Mayo 2019 07:45

Detiček A, Locatelli I, Kos M. Patient Access to Medicines for Rare Diseases in European Countries. Value Health. 2018; 21(5): 553-560.

European Reference Networks for rare diseases: what is the conceptual framework?

Héon-Klin V. European Reference Networks for rare diseases: what is the conceptual framework? Orphanet J Rare Dis. 2017; 12: 137. Published online 2017 [DOI: 10.1186/s13023-017-0676-3].

Comentado por:

Marta Trapero-Bertran
Profesora titular e Investigadora de la Universitat Internacional de Catalunya (UIC)

Determining the value of medical technologies to treat ultra-rare disorders: a consensus statement

Schlander M, Garattini S, Kolominsky-Rabas P, Nord E, Persson U, Postma M, et al. Determining the value of medical technologies to treat ultra-rare disorders: a consensus statement. J Market Access Health Policy. 2016; 4: 33039 [DOI: 10.3402/jmahp.v4.33039]

Comentado por:

Marta Trapero-Bertran
Profesora titular e Investigadora de la Universitat Internacional de Catalunya (UIC)

Recommendations from the European Working Group for Value Assessment and Funding Processes in Rare Diseases (ORPH-VAL)

Annemans L, Aymé S, Le Cam Y, Facey K, Gunther P, Nicod E, et al. Recommendations from the European Working Group for Value Assessment and Funding Processes in Rare Diseases (ORPH-VAL). Orphanet J Rare Dis. 2017; 12: 50

Comentado por:

Jaime Espín
Profesor de la Escuela Andaluza de Salud Pública

Página 2 de 3